US Patent

US11844758 — Therapeutically active compounds and their methods of use

Method of Use · Assigned to Servier Pharmaceuticals LLC · Expires 2035-12-04 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods for treating cancer, as described in the provided compounds.

USPTO Abstract

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Drugs covered by this patent

Voranigo (VORASIDENIB) · Servier

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3977`	—	Voranigo
`U-3977`	—	Voranigo

Patent Metadata

Patent number: US11844758
Jurisdiction: US
Classification: Method of Use
Expires: 2035-12-04
Drug substance claim: No
Drug product claim: No
Assignee: Servier Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.